Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (238 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-02-25. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: ivimmunogenicitypriorvaccinemalignancy
  Phrases that lowered it: volunteersdrugparticipantsthe studyhealthy
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 4.9% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 62.7% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 118466 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects NCT02923583 · started 2016 · scored riskier than 4% of active trials completed
• Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS NCT04018599 · started 2019 · scored riskier than 2% of active trials completed
• Pharmacokinetics and Safety of BI 695501 NCT02899338 · started 2016 · scored riskier than 6% of active trials completed
• A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects. NCT06929052 · started 2025 · scored riskier than 2% of active trials completed
• This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS). NCT06738277 · started 2025 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.